Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study
Open Access
- 7 August 2009
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 275
- https://doi.org/10.1186/1471-2407-9-275
Abstract
Cervical cancer and infection with human immunodeficiency virus (HIV) are both important public health problems in South Africa (SA). The aim of this study was to determine the prevalence of cervical squamous intraepithelial lesions (SILs), high-risk human papillomavirus (HR-HPV), HPV viral load and HPV genotypes in HIV positive women initiating anti-retroviral (ARV) therapy. A cross-sectional survey was conducted at an anti-retroviral (ARV) treatment clinic in Cape Town, SA in 2007. Cervical specimens were taken for cytological analysis and HPV testing. The Digene Hybrid Capture 2 (HC2) test was used to detect HR-HPV. Relative light units (RLU) were used as a measure of HPV viral load. HPV types were determined using the Roche Linear Array HPV Genotyping test. Crude associations with abnormal cytology were tested and multiple logistic regression was used to determine independent risk factors for abnormal cytology. The median age of the 109 participants was 31 years, the median CD4 count was 125/mm3, 66.3% had an abnormal Pap smear, the HR-HPV prevalence was 78.9% (Digene), the median HPV viral load was 181.1 RLU (HC2 positive samples only) and 78.4% had multiple genotypes. Among women with abnormal smears the most prevalent HR-HPV types were HPV types 16, 58 and 51, all with a prevalence of 28.5%. On univariate analysis HR-HPV, multiple HPV types and HPV viral load were significantly associated with the presence of low and high-grade SILs (LSIL/HSIL). The multivariate logistic regression showed that HPV viral load was associated with an increased odds of LSIL/HSIL, odds ratio of 10.7 (95% CI 2.0 – 57.7) for those that were HC2 positive and had a viral load of ≤ 181.1 RLU (the median HPV viral load), and 33.8 (95% CI 6.4 – 178.9) for those that were HC2 positive with a HPV viral load > 181.1 RLU. Women initiating ARVs have a high prevalence of abnormal Pap smears and HR-HPV. Our results underscore the need for locally relevant, rigorous screening protocols for the increasing numbers of women accessing ARV therapy so that the benefits of ARVs are not partially offset by an excess risk in cervical cancer.Keywords
This publication has 37 references indexed in Scilit:
- The Impact of HIV Status and Type on the Clearance of Human Papillomavirus Infection among Senegalese WomenThe Journal of Infectious Diseases, 2007
- Prevalence and distribution of HPV genotypes among HIV-infected women in ZambiaBritish Journal of Cancer, 2007
- Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, ZambiaGynecologic Oncology, 2006
- Human papillomavirus types among women infected with HIV: a meta-analysisAIDS, 2006
- Prevalence of Human Papillomavirus Genotypes and Related Abnormalities of Cervical Cytological Results among HIV‐1–Infected Women in Rochester, New YorkThe Journal of Infectious Diseases, 2006
- Associations of high-risk HPV types and viral load with cervical cancer in ChinaJournal of Clinical Virology, 2005
- Epidemiologic Profile of Type‐Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa RicaThe Journal of Infectious Diseases, 2005
- High risk HPV load estimated by Hybrid Capture II® correlates with HPV16 load measured by real-time PCR in cervical smears of HPV16-infected womenJournal of Clinical Virology, 2004
- Increased Risk of High‐Grade Cervical Squamous Intraepithelial Lesions and Invasive Cervical Cancer among African Women with Human Immunodeficiency Virus Type 1 and 2 InfectionsThe Journal of Infectious Diseases, 2003
- The Significance of Human Papillomavirus Viral Load in Prediction of Histologic Severity and Size of Squamous Intraepithelial Lesions of Uterine CervixGynecologic Oncology, 2001